Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons

Authors :: Nischal Ranganath
John C O’Horo
Douglas W Challener
Sidna M Tulledge-Scheitel
Marsha L Pike
Michael O’Brien
Raymund R Razonable
Aditya Shah
Source :: Clinical Infectious Diseases. 76:e537-e539
Publication Year :: 2022
Publisher :: Oxford University Press (OUP), 2022.
Abstract: In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19–directed therapy.

Full Text Access

Tools